Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Open-Label Controlled Study of EMD 72000 (Matuzumab), in Combination With the Chemotherapy Regimen ECX or the Chemotherapy Regimen ECX Alone as First-line Treatment in Subjects With Metastatic Esophago-Gastric Adenocarcinoma

Trial Profile

Randomized Phase II Open-Label Controlled Study of EMD 72000 (Matuzumab), in Combination With the Chemotherapy Regimen ECX or the Chemotherapy Regimen ECX Alone as First-line Treatment in Subjects With Metastatic Esophago-Gastric Adenocarcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2018

At a glance

  • Drugs Matuzumab (Primary) ; Capecitabine; Cisplatin; Epirubicin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms MATRIX EG
  • Most Recent Events

    • 12 Nov 2008 Status changed from active, no longer recruiting to completed, as reported in ClinicalTrials.gov record.
    • 18 Feb 2008 Takeda and its partner Merck KGaA have decided to no longer jointly pursue development of matuzumab, based on the clinical findings to date.
    • 06 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top